Product Description
Uzansertib is an orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, uzansertib binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Uzansertib)
Mechanisms of Action: BCL2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Incyte
Company Location: WILMINGTON DE 19803
Company CEO: Hervé Hoppenot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Myelofibrosis|Multiple Myeloma|Lymphoproliferative Disorders|Acute Myeloid Leukemia|Conduct Disorder|Myelodysplastic Syndrome|Lymphoma|Myeloproliferative Disorders
Phase 1: Multiple Myeloma|Diffuse Large B-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IIT-Dhakal-INCB053914 | P1 |
Withdrawn |
Multiple Myeloma |
2023-07-01 |
|
| INCB 53914-102 | P1 |
Completed |
Diffuse Large B-Cell Lymphoma |
2020-09-01 |
41% |
| INCB 53914-101 | P2 |
Terminated |
Myelofibrosis|Acute Myeloid Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Myeloproliferative Disorders|Lymphoma|Lymphoproliferative Disorders|Conduct Disorder |
2020-08-11 |